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Abstract: Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased understanding
of disease pathobiology and genomics has led to clinical investigation of novel targeted therapies and rational
combinations. Targeting the cyclin-dependent kinase 9 (CDK9) pathway, which is dysregulated in AML, is an
attractive approach. Inhibition of CDK9 leads to downregulation of cell survival genes regulated by super enhancers such
as MCL-1, MYC, and cyclin D1. As CDK9 inhibitors are nonselective, predictive biomarkers that may help identify patients
most likely to respond to CDK9 inhibitors are now being utilized, with the goal of improving efficacy and safety.
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Background
Acute myeloid leukemia (AML) is a heterogeneous
hematologic malignancy characterized by a clonal pro-
liferation of immature myeloid precursor cells in the
peripheral blood, bone marrow, and/or other tissues. It
is the most common acute adult leukemia, with approxi-
mately 21,380 individuals in the United States diagnosed
in 2017 [1]. AML is primarily a disease of older adults,
with a median age at diagnosis of 68 years. It may develop
de novo or secondarily due to progression of myelodys-
plastic syndrome (MDS) or chronic bone marrow stem
cell disorders [2] or as a result of prior cytotoxic chemo-
therapy, particularly alkylating agents and topoisomerase
inhibitors [3].
Treatment for AML has been less than optimal. The
standard induction regimen, a continuous infusion of
cytarabine for 7 days plus 3 days of an anthracycline,
usually daunorubicin or idarubicin (7 + 3 therapy), has
changed little over the past 40 years. Complete remis-
sion (CR) rates rarely top 70% in younger patients and
50% in older patients [4], and overall 5-year survival is
only 27% [1]. Over the 3 decades from 1977 to 2006,
there has been a modest improvement in overall survival
for patients aged 64 to 75 years, but not for those
75 years or older [5]. The prognosis for primary refrac-
tory and relapsed or refractory (R/R) AML is particularly
poor [6, 7]. After first relapse, 1- and 5-year survival
rates of 29% and 11%, respectively, have been reported
[7]. These poor outcomes necessitate new treatment op-
tions for the disease, including those that overcome drug
resistance.
An increasing understanding of the pathobiology and
genomics of AML has led to clinical investigation of a
variety of novel therapeutic approaches, particularly agents
targeted against dysregulated enzymes and mutant driver
proteins. In addition, investigations into mechanisms of
drug resistance in AML have shed light on means of over-
coming chemoresistance, such as targeting leukemic stem
cells and the bone marrow microenvironment [8–10]. Two
new targeted agents were approved by the US Food and
Drug Administration (FDA) in 2017, representing the first
new AML drugs available since 2000. Midostaurin, a small
molecule kinase inhibitor, was approved for use in combin-
ation with standard cytarabine and daunorubicin induction
and cytarabine consolidation chemotherapy for the treat-
ment of adult patients with newly diagnosed FLT3-mutated
AML [11]. Enasidenib, an oral targeted inhibitor of the iso-
citrate dehydrogenase-2 (IDH2) enzyme, was approved for
the treatment of adult patients with R/R AML with an
IDH-2 mutation as detected by an FDA-approved test [12].
In addition, gemtuzumab ozogamicin, which originally re-
ceived accelerated approval in 2000 but was voluntarily
withdrawn from the market, was also approved for the
treatment of adults with newly diagnosed CD33-positive
AML and for patient 2 years and older with R/R CD33-
positive AML [13]. In addition to these targeted agents,
a liposome-encapsulated combination of daunorubicin
and cytarabine was approved for the treatment of adults
with newly diagnosed therapy-related AML or AML
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with myelodysplasia-related changes, both of which have a
poor prognosis [14].
A therapeutic target that has been investigated in
AML is cyclin-dependent kinase (CDK)9, one of a large
number of CDKs that control cell-cycle progression and
gene transcription. Although originally thought to act
via cell-cycle regulation, CDK9 is involved in regulating
gene transcription elongation and messenger RNA (mRNA)
maturation, as well as other physiologic processes [15, 16].
Dysregulation in the CDK9 pathway has been observed in
AML and other hematologic malignancies and in solid tu-
mors, making it an attractive target for cancer therapeutics
[17]. In this review, we provide an updated overview of the
biology of CDK9 and describe the role of the CDK9
pathway in AML, providing rationale supporting its use
as a therapeutic target. This is followed by a review of
CDK9 inhibitors in clinical and preclinical development
for AML and other hematologic malignancies.
Biology of CDK9
Together with regulatory subunits (cyclins), CDKs form
functional complexes responsible for the control of cell
proliferation, differentiation, apoptosis, and DNA repair
[17]. Whereas many CDKs (eg, CDK1, CDK2, CDK3,
CDK4, and CDK6) control cell-cycle progression, ensur-
ing timely and accurate cell replication, others (ie, CDK8
and CDK9) function as gene transcription controllers
[18]. CDK9 plays a critical role in controlling global
(non-ribosomal) transcription, notably including expres-
sion of genes that are regulated by super enhancers,
large clusters of DNA regulatory elements (“enhancers”)
that drive transcription of genes involved in cell identity
[19]. Such genes include MYC, a downstream proto-
oncogene involved in cell growth and cell-cycle progression,
and MCL-1, an apoptosis regulator. CDK9 also appears to
be involved in several physiologic processes in the cell out-
side of transcription, including differentiation, apoptosis,
and signal transduction [15].
CDK9 was first designated PITALRE based on a charac-
teristic amino acid motif (Pro-Ile-Thr-Ala-Leu-Arg-Glu),
and its function was first elucidated in studies of human
immunodeficiency virus [20, 21]. CDK9 exists in two iso-
forms, the originally identified major 42 kDa protein
(CDK942) and a minor 55 kDa (CDK955) protein that is
translated from an in-frame mRNA that arises from an
upstream transcriptional start site [22, 23].
Both CDK9 isoforms generate a heterodimer with
regulatory cyclins T1, T2a, or T2b to form the main
component of the positive transcription elongation fac-
tor b (P-TEFb) complex that stimulates transcription
elongation by phosphorylating the carboxy-terminal do-
main (CTD) of the largest subunit of RNA polymerase II
(RNA Pol II); the CTD contains tandem repeats of a 7
amino-acid sequence that is phosphorylated by CDK7 at
Ser5 (YSPTSer5PS) and CDK9 at Ser2 (YSer2PTSPS).
Ser5 phosphorylation results in activation of RNA Pol II
such that transcription is initiated and Ser2 phosphoryl-
ation allows productive transcriptional elongation (Fig. 1
[15]). Therefore CDK9 inhibition prevents productive
transcription and is associated with a global reduction in
mRNA, including genes, such as MYC and MCL-1,
which regulate proliferation and survival of cancer cells
Fig. 1 Role of cyclin-dependent kinase (CDK)9 in gene transcription and cancer cell survival. CDK9 associates with cyclin T1 (CycT), forming the
positive transcription elongation factor b (P-TEFb) complex that regulates gene transcription elongation and mRNA maturation [15]. The P-TEFb
complex remains inactive when bound to hexamethylene bisacetamide-inducible protein 1 (HEXIM1), which is associated with the noncoding
7SK small nuclear RNA (snRNA) [45]. Bromodomain protein 4 (BRD4) recruits P-TEFb to activate the complex and transcription. CDK9 phosphorylates
the carboxyl terminal domain of RNA polymerase II (RNA Pol II), allowing transcriptional elongation and expression of genes such as MYC and MCL-1,
which together increase proliferation and survival of cancer cells
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[15, 24–26]. Cyclin K can also interact with CDK9 iso-
forms in vitro and in vivo, and the CDK9–cyclin K com-
plex can activate transcription when tethered to RNA,
but not to DNA, in vitro [24]. Further investigations
have shown that CDK9 is involved in co-transcriptional
histone modification, mRNA processing, mRNA export,
and DNA repair [16, 27, 28].
Although their phosphorylation patterns may be iden-
tical, the CDK9 isoforms display differences in subcellu-
lar localization and expression patterns, regulation, and
tissue distribution [23, 28]. CDK42 has been reported to
localize to the nucleoplasm whereas CDK955 localizes to
the nucleolus [23, 26]. Also, CDK55, but not CDK942,
specifically associates with Ku70 and appears to play a
role in DNA repair and cell viability through a distinct
function [28]. In addition, there are numerous reports of
differential expression patterns, including in hematologic
cells [25]. Interestingly, CDK955 is preferentially expressed
following induced differentiation of human primary
monocytes into macrophages [23], whereas stimulation of
human macrophages with lipopolysaccharide, or infection
with the human immunodeficiency virus type 1 (HIV-1)
increases CDK942 expression [29]. Also activation of
primary lymphocytes results in increased CDK942 and
decreased CDK955 expression [23]. Taken together, these
findings suggest that the function of the two CDK9
isoforms is likely to be at least partially distinct, al-
though further studies are required to produce defini-
tive evidence [26] and importantly in the cancer context,
including in AML.
Role of the CDK9 pathway in cancers, including AML
The CDK9-related pathway has emerged as a prioritized
target for cancer therapy across a range of tumor types
[30]. Multiple studies have shown that a dysregulated
CDK9 signaling system may have important implications
in the development and/or maintenance of a malignant
cell phenotype [30]. Dysregulation of the CDK9 pathway
has been observed in a variety of human tumors, which
may induce increased expression and/or hyperactivity of
cellular oncogenic factors. Studies on cancers, such as
lymphoma [31, 32], prostate cancer [33], neuroblastoma
[34], and other malignancies [35], demonstrate that CDK9-
related pathways are dysregulated, suggesting that CDK9
overexpression promotes the cell proliferation and the
synthesis of antiapoptotic factors like MCL-1, BCL,-2
and XIAP [36], which are determinants for cancer-cell
survival [37]. The levels of gene products with short
half-lives, such as MYC and MCL-1, are reduced most
rapidly on exposure to CDK9 inhibitors, thereby lead-
ing to reduced cell proliferation and survival.
Regarding CDK9 expression in AML, the HemaExplorer
[38] curated database of processed mRNA gene expres-
sion profiles provides accessible data on CDK9 expression
in hematopoietic cells at different maturation stages.
Expression data from distinct subtypes of human AML,
defined by karyotypes, are included in the database
allowing researchers to directly compare gene expression
of leukemic cells with those of their closest normal coun-
terparts. Such data point to a numeric increase in CDK9
mRNA expression in AML samples relative to common
myeloid progenitor cells and also illustrates some variation
in expression between AML subtypes.
However, it is important to note that overall CDK9
pathway activity is a critical aspect of dysregulation rather
than CDK9 expression only. Critically, CDK9-mediated
transcription of MCL-1 and MYC plays an important role
in growth and survival of cancer cells, and dysregulation
of this component of the CDK9 pathway is prominent in a
number of hematologic malignancies [17]. The MCL-1
and MYC aspects of the CDK9 pathway have been as-
sociated with the pathogenesis of AML. For example,
various translocation products of the MLL gene found
in leukemias such as AML associate with P-TEFb and
constitutively activate transcription [17, 39]. High MCL-1
expression is linked to AML development in murine models
[40], and MCL-1 plays a key role in survival and expansion
of murine and human AML cells [41]. MCL-1 is also upreg-
ulated in about half of cases of R/R AML and is associated
with a poor prognosis [42]. Levels of the P-TEFb inhibitor
hexamethylene bisacetamide-inducible protein 1 (HEXIM1)
are upregulated during differentiation of murine leukemia
cells [43], and HEXIM1 has been shown to be involved in
the tumorigenesis of AML cell lines bearing the NPMc
+ mutation, the cytoplasmic-mislocated mutant form of
NPM seen in approximately 35% of patients with AML [44].
In addition, HEXIM1 mRNA overexpression is almost mu-
tually exclusive with MYC overexpression in primary AML
samples, suggesting that HEXIM1 plays a key role in the
growth inhibition and apoptosis of AML cells [45].
Such disease linkage evidence encouraged studies
evaluating the potential of CDK9 inhibitors as anticancer
therapeutics, initially in pre-clinical models. CDK9 inhib-
ition has been reported to lead to apoptosis in a variety of
leukemia and solid tumor cell lines. Notably, the most sen-
sitive cancer cells lines included hematologic tumor cells,
especially AML [46], thereby providing functional evidence
for the dependency of AML on the CDK9 pathway.
Given CDK9 is a kinase it is considered as a relatively
tractable target for drug discovery and provides a route
for the indirect targeting of MCL-1 and MYC that may
be considered as currently more challenging targets in
drug discovery [32].
CDK9 inhibitors in clinical trials in AML and other
hematologic cancers
CDK9 inhibitors have been investigated as therapeutics
for a variety of hematologic cancers and solid tumors.
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Table 1 [46–59] provides CDK inhibition profiles for
CDK9 inhibitors that have reached the clinic or have
been evaluated in preclinical studies in AML and other
hematologic cancers (Additional file 1: Table S1 summa-
rizes the clinical status of other CDK9 inhibitors across
a broader range of tumor types). Current CDK9 inhibi-
tors are competitive inhibitors of the ATP-binding site,
which is highly conserved across the CDK family; conse-
quently CDK9 inhibitors lack specificity and generally
also inhibit other CDKs to varying extents [60, 61]. Al-
though some progress has been made against other
CDKs in discovery of allosteric inhibitors with greater
selectivity potential by targeting residues outside the kin-
ase domain (CDK12/13 [62, 63]), no such inhibitors have
been described for CDK9. Although they display activity
against a variety of CDKs and enzymes, CDK9 inhibitors
are referred to as such because they typically exhibit in-
creased half maximal inhibitory concentration (IC50)
values for CDK9 compared with other CDKs/enzymes.
As described in the sections that follow, CDK9 inhibitors
in general exhibit a variety of effects in AML cells and in
vivo models, including reduced phosphorylation of RNA
Pol II; reduced levels of proteins such as MYC, MCL-1,
XIAP, and cyclin D1; induction of apoptosis; and inhib-
ition of tumor growth and prolonged survival in animal
models. There is increasing interest in identifying pre-
dictive biomarkers of response to conventional and
investigational-targeted therapies in AML, including
CDK9 inhibitors. For example, measuring the function
of B-cell lymphoma 2 (BCL-2) family proteins using
BCL-2 homology domain 3 (BH3) profiling has been
shown to provide useful information in discriminating
Table 1 CDK9 inhibitors
Agent Mode of Administration CDK Inhibition Profile (IC50) Development Stage/Indication
Alvocidib (flavopiridol) [47, 48] Intravenous CDK9: 6 nM
CDK4: 10 nM
CDK7: 23 nM
CDK11: 57 nM
CDK5: 110 nM
Phase 2: AML, ALL, CLL, DLBCL, MCL, MM, various
lymphomas
Phase 1: AML, ALL, B-cell CLL, CML, MCL, SLL, various
lymphomas
AT7519 [49] Intravenous CDK9: < 10 nM CDK5: 13 nM
CDK2: 47 nM
CDK4: 100 nM
CDK6: 179 nM
Phase 2: CLL, MCL
BAY 1143572 [50] Oral Not published Phase 1: AML, ALL, DLBCL
CDKI-73 (LS-007) [51, 52] Intravenous, oral CDK2: 3 nM
CDK9: 6 nM
CDK1: 8 nM
CDK4: 8 nM
CDK6: 37 nM
CDK7: 134 nM
Preclinical
Dinaciclib [53, 54] Intravenous CDK2: 1 nM
CDK5: 1 nM
CDK1: 3 nM
CDK9: 4 nM
Phase 3: CLLa
Phase 2: AMLa, ALLa, B-cell CLLa, MCLa, MM
Phase 1: CLL, DLBCL, MM
LY2857785 [46] Intravenous CDK9: 11 nM
CDK8: 16 nM
CDK7: 246 nM
Preclinical
P276–00b [55, 56] Intravenous CDK9: 20 nM
CDK4: 63 nM
CDK1: 79 nM
CDK2: 224 nM
Phase 2: MCLa, MM
Phase 1: MM
SNS-032 (BMS-387032) [57, 58] Intravenous CDK9: 4 nM
CDK2: 38 nM
CDK7: 62 nM
Phase 1: CLL, MM
TG02 [59] Oral CDK9: 3 nM
CDK5: 4 nM
CDK2: 5 nM
CDK3: 8 nM
CDK1: 9 nM
CDK7: 37 nM
Phase 1: AML, CML, SLL
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CDK, cyclin-dependent kinase; CLL, chronic lymphocytic leukemia; CML, chronic myeloid
leukemia; DLBCL, diffuse large B-cell lymphoma; IC50, half maximal inhibitory concentration; MCL, mantle cell lymphoma; MM, multiple myeloma; SLL, small
lymphocytic lymphoma
aStudy terminated
bDevelopment discontinued
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AML treatment response with traditional cytarabine-based
therapy and investigational AML regimens [64–68]. The
underlying principle of BH3 profiling is that mitochondrial
depolarization following exposure to BH3 domain peptides
serves as a functional biomarker to predict cell sensitivity
to individual antiapoptotic proteins [69]. For example, sen-
sitivity of cells to the NOXA-BH3 peptide provides a direct
functional measurement of MCL-1 dependency, whereas
sensitivity of cells to BAD-BH3 provides a measurement of
BCL-2 dependency.
Alvocidib (flavopiridol)
Alvocidib was the first CDK inhibitor to enter clinical
trials and has been the most studied to date. Alvocidib
displays potent activity against CDK9 (6 nM), in addition
to activity against CDK4, CDK5, CDK7, and CDK11
[47, 48]. Although historically the mechanism of action
of alvocidib was attributed to inhibition of the cell cycle
at the G1 phase via targeting of CDK4/6 [70], it is now
understood that its primary mechanism of action is via
transcriptional regulation via CDK9/P-TEFb [71].
In vitro studies in diverse hematologic malignancies
and studies on human on AML marrow blasts have
shown that alvocidib reduces levels of MCL-1, BCL-2,
and cyclin D1 and inhibits phosphorylation of RNA Pol
II (reviewed in Karp, 2005) [72]. Based on its noted ef-
fects on the cell cycle, transcription, and apoptosis, it was
surmised that alvocidib could potentiate the cytotoxicity
of cycle-dependent antileukemic agents. To evaluate the
potential use of alvocidib in timed sequential therapy
(TST) in the clinical setting, an in vitro model was devel-
oped using primary human bone marrow cells from adults
with R/R AML, acute lymphoblastic leukemia (ALL), or
newly diagnosed AML with poor risk features [73]. In this
model, alvocidib induced a 4.3-fold increase in apoptosis
and increased the proapoptotic and cytotoxic effects of
cytarabine. Subsequent studies in AML cell lines corre-
lated rapid downregulation of MCL-1 and a 2-fold reduc-
tion in MCL-1 levels with enhanced apoptosis [74]. Gene
expression studies in leukemic blasts from adult patients
with refractory AML treated with alvocidib in a phase 1
study demonstrated induced expression of BCL-2, which
contrasts with earlier studies demonstrating downregula-
tion of BCL-2 expression and may represent a protective
antiapoptotic response during cell-cycle arrest [75]. Alvo-
cidib administration also resulted in downregulation of
genes encoding RNA Pol II and the oncogenic tran-
scription factors high mobility group AT-hook 1, signal
transducer and activator of transcription 3, and E2F
transcription factor 1, which are known to be involved
in AML and other hematologic malignancies.
Alvocidib was evaluated in combination with cytara-
bine and mitoxantrone (FLAM) in a TST manner in
multiple clinical studies in R/R AML [48, 72, 76, 77] and
newly diagnosed, nonfavorable AML [76, 78–80]. A re-
view of the safety and efficacy results from these individual
studies has recently been published [80] and is beyond the
scope of this review. In phase 2 trials in newly diagnosed
poor-risk AML, overall CR rates of 67% to 75% were
achieved, which were higher than that seen with standard
7 + 3 therapy [76, 78–80]. In general, toxicity seen with
FLAM was not increased over that seen with 7 + 3 ther-
apy, with febrile neutropenia, infection, and hepatic dys-
function being the most common Grade 3 toxicities
reported in the latest study [80]. Treatment-related mor-
tality was similar in both treatment arms in this study, but
the majority of early deaths on FLAM occurred in pa-
tients ≥60 years. Tumor lysis syndrome (TLS) has been
seen following initial dosing of alvocidib in AML stud-
ies (28% incidence overall, with 2% Grade 4), necessitat-
ing appropriate prophylaxis and monitoring [80].
There are ongoing efforts to determine predictive bio-
markers to allow identification of specific subsets of pa-
tients who are likely to respond to alvocidib, such as use
of BH3 profiling [66]. As NOXA interacts most directly
with MCL-1, these findings suggest that the AML sam-
ples that are most responsive to FLAM treatment are
highly dependent on MCL-1 for survival. MCL-1 de-
pendency was also supported by data obtained using
three additional BH3 members, and these BH3 priming
profiles were additive to known risk factors associated
with clinical response to chemotherapy, including cyto-
genetic risk factors. Receiver operating characteristic curve
analysis of NOXA priming, cytogenetics, and MDS history
showed that the combination of these variables was
highly predictive of response to FLAM (area under the
concentration-time curve 0.92, p= 0.0002). An ongoing inter-
national biomarker-driven phase 2 study (NCT02520011)
is incorporating this predictive information in identifying
a subgroup of patients most likely to respond to alvocidib.
The study is comparing FLAM vs. cytarabine and mitox-
antrone (AM) in patients with MCL-1-dependent R/R
AML as demonstrated by NOXA-BH3 priming of ≥40%
by mitochondrial profiling of the bone marrow. It includes
an exploratory arm evaluating patients with newly diag-
nosed MCL-1-dependent high-risk AML.
A phase 1, open-label, dose-escalation, safety and bio-
marker prediction study was recently registered. This study
will explore alvocidib and standard 7 + 3 chemotherapy in
patients with newly diagnosed AML (NCT03298984). Cor-
relation between the benefit from alvocidib in combination
with 7 + 3 therapy and BH3 profiling for MCL-1 depend-
ency will be assessed as a secondary outcome.
Bay 1143572
BAY 1143572 displays potent CDK9/P-TEFb inhibitory
activity in the nanomolar range, with inhibitory activ-
ity against other CDKs that is at least 50-fold lower
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[50, 81]. In in vitro models of adult T-cell leukemia/
lymphoma (ATL), BAY 1143572 inhibited phosphoryl-
ation of RNA Pol II and reduced MYC and MCL-1
levels in ATL-derived and human T-lymphotropic
virus 1 (HTLV-1)-transformed lines and primary ATL
cells, with subsequent growth inhibition and apoptosis
[50]. It also displayed antitumor activity and prolonged
survival in a human ATL cell-bearing mouse model. In
AML, BAY 1143572 inhibited the proliferation of 7 cell
lines (both MLL-rearrangement positive and negative)
with a median IC50 of 385 nM and induced apoptosis [82].
In addition, it displayed potent in vitro activity in 8 of 10
non-MLL-rearranged patient AML samples, including
those with mutant NPM1 or internal tandem duplication
of the juxtamembrane domain-coding sequence of the
FLT3 gene (FLT3-ITD).
A phase 1 dose escalation study of BAY 1143572 in
combination with granulocyte colony-stimulating factor
in patients with advanced malignancies (ie, gastric can-
cer, triple negative breast cancer, or diffuse large B-cell
lymphoma [DLBCL]; NCT01938638) has been completed,
but results are yet to be reported. A phase I dose-escal-
ation study designed to determine the safety, pharmaco-
kinetics, and recommended phase 2 dosing of BAY
1143572 in advanced acute leukemia has completed en-
rollment (NCT02345382).
Dinaciclib (SCH 727965)
Dinaciclib is a novel and potent inhibitor of CDK1,
CDK2, CDK5, and CDK9 with IC50 values in the low
nanomolar range [53]. In in vitro studies, dinaciclib
blocked thymidine DNA incorporation (IC50 = 4 nM) and
completely suppressed retinoblastoma (Rb) phosphoryl-
ation, which correlated with induction of apoptosis. Dinaci-
clib exposure resulted in cell-cycle arrest in more than 100
tumor cell lines of diverse origin and across a broad range
of transformed cellular backgrounds as evidenced by based
on total inhibition of bromodeoxyuridine incorporation.
Broad antiproliferative activity was seen across this panel
of tumor cell lines, with median IC50 values of 11 nM.
Dinaciclib has also been shown to downregulate expression
of MCL-1 and induce apoptosis in primary patient chronic
lymphocytic leukemia (CLL) cells, with activity that was in-
dependent of high-risk genomic features [83].
Apoptotic and antitumor effects of dinaciclib were dem-
onstrated in MLL-rearranged AML mouse models [84].
Decreased expression of Mcl-1 was seen and overex-
pression of Mcl-1 protected AML cells from dinaciclib-
induced apoptosis. In mice bearing MLL-AF9-driven
murine and human leukemias, dinaciclib exhibited potent
antitumor activity and significantly prolonged survival.
Dinaciclib has been evaluated in clinical trials in vari-
ous hematologic indications, with varied effectiveness. In
a phase 2 study of dinaciclib monotherapy in patients
with relapsed multiple myeloma (MM), 11% of patients
achieved a partial response or better [54]. The most
common adverse events included diarrhea, fatigue,
thrombocytopenia, nausea, leukopenia, and neutropenia.
Results were reported for three additional hematologic
studies that were terminated early for reasons unrelated
to safety or efficacy [85–87].
A phase 2 randomized study comparing dinaciclib and
gemtuzumab ozogamicin in R/R AML and evaluating
dinaciclib in ALL (NCT00798213) demonstrated short-
lived cytoreductive activity with dinaciclib but a lack of
objective clinical response in the 20 patients treated
[85]. In addition, 75% of patients receiving dinaciclib
experienced grade ≥ 3 treatment-related adverse events,
most commonly hematologic toxicities and fatigue.
Interestingly, an additional clinical toxicity reported
was TLS, where metabolic changes indicative of large-
scale tumor cell lysis occur [85]. While this phenomenon
requires careful monitoring and management, this pro-
vides further evidence of potent anti-tumor activity under-
lying the cytoreductive observations, albeit currently short
term in duration. This may be interpreted as illustrating
the potential of CDK9-targeted therapy. Indeed, given the
rapid clinical elimination of dinaciclib together with its
potent cytotoxic effects observed on longer exposure in in
vitro studies, evaluation of alternative clinical dosing regi-
mens such as prolonged infusion are proposed for future
studies in acute leukemia [85]. Clearly, other consider-
ations, such as tolerability and the intended selective tar-
geting of short-lived antiapoptotic proteins such as MCL-
1 and MYC, will also need to be considered when optimiz-
ing the drug exposure period and schedule.
A randomized phase 3 study in which 42 patients with
R/R CLL received treatment suggested promising anti-
leukemic activity with dinaciclib relative to ofatumumab,
an anti-CD20 monoclonal antibody (median progression-
free survival of 13.7 months vs. 5.9 months, and overall re-
sponse rate of 40% vs. 8.3%, respectively) [86]. The most
common grade ≥ 3 adverse events experienced by patients
receiving dinaciclib were neutropenia/reduced neutrophil
counts/febrile neutropenia and thrombocytopenia. Limited
data from five patients treated in a phase 1 study evaluating
the combination of dinaciclib and rituxumab in R/R CLL
showed an adverse event profile similar to that seen with
dinaciclib monotherapy [87]. No results have been reported
for a discontinued phase 2 study in R/R mantle cell lymph-
oma and B-cell CLL (NCT00871546). Dinaciclib is being
evaluated in combination with pembrolizumab in R/R
hematologic malignancies (ie, CLL, MM, and DLBCL) in
an ongoing phase 1 trial (NCT02684617).
SNS-032 (BMS-387032)
SNS-032, a potent CDK9 inhibitor (4 nM) with activity
against CDK2 and CDK7, was evaluated in a phase 1
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and pharmacologic study in patients with advanced CLL
or MM [57, 58]. Mechanism-based target modulation
(ie, inhibition of CDK7 and CDK9, reduced MCL-1 and
XIAP expression, and apoptosis) was demonstrated, but
limited clinical activity was seen and three-quarters of
the patients experienced grade 3 or 4 toxicities, mainly
myelosuppression [58]. In vitro studies showed that
SNS-032 inhibited proliferation of AML cell lines and
primary AML blasts by inducing a reduced phosphoryl-
ation of Ser2, leading to RNA Pol II pausing and result-
ing in Ser5 dephosphorylation after a period of time
[88]. Combining SNS-032 with cytarabine was synergis-
tic, causing reduced expression of the antiapoptotic
genes XIAP, BCL-2, and MCL-1.
TG02
TG02 is an oral CDK9 inhibitor with activity against sev-
eral CDKs in the nanomolar range [59]. TG02 exhibited
potent antiproliferative effects against various tumor cell
lines, induced cell-cycle arrest and apoptosis in murine
mutant FLT3 leukemia cells, and induced tumor regres-
sion and prolonged survival in murine AML models. In
primary AML patient samples, TG02 inhibited transcrip-
tion by inducing RNA Pol II Ser2 dephosphorylation
and downregulated MCL-1 and XIAP, leading to subse-
quent BAX activation and apoptosis [89]. Dynamic BH3
profiling has demonstrated that TG02 sensitizes to the
BCL-2-inhibitory BAD-BH3 peptide in AML cells [68].
In addition, TG02 was shown to synergize with the BCL-2
antagonist venetoclax (ABT-199), which sensitizes to the
MCL-1-inhibitory NOXA-BH3 peptide, to induce apop-
tosis in AML cells.
Phase 1 studies evaluating TG02 in advanced hematologic
malignancies (ie, relapsed AML or ALL, chronic myeloid
leukemia in blast crisis, or MDS; NCT01204164) and in R/R
CLL or small lymphocytic lymphoma (NCT01699152), have
been completed.
CDK9 inhibitors in preclinical development in AML and
other hematologic cancers
CDKI-73 (LS-007)
CDKI-73 is a potent CDK9 inhibitor (IC50 = 6 nM) that
also displays strong activity against CDK1, CDK2, and
CDK4 [51]. CDKI-73 inhibited phosphorylation of RNA
Pol II Ser2 and transcription of MCL-1 and XIAP, and
induced apoptosis, in primary CLL cells and in AML
and ALL cell lines [51, 52]. In CLL cells, CDKI-73 in-
duced apoptosis via caspase-3 activation and displayed
synergistic activity when combined with fludarabine,
reversing the increase in MCL1 and XIAP seen with
fludarabine alone [52]. CDKI-73 also decreased survival of
primary AML and ALL cells and displayed synergism
with the BCL-2 inhibitor ABT-199 against acute leukemia
cell lines [51].
LY2857785
LY2857785 is a potent CDK9 inhibitor (IC50 = 11 nM)
that also displays activity against CDK8, as well as CDK7
to a lesser degree [46]. LY2857785 was shown to inhibit
Ser2 and Ser5 of RNA Pol II in primary AML and CLL
cells and in an orthotopic leukemia model. It also inhib-
ited cell proliferation of a variety of leukemia and solid
tumor cell lines and reduced levels of MCL-1, resulting
in apoptosis.
Conclusions
Inhibition of CDK9 leads to selective downregulation of
cell survival genes regulated by super enhancers and
with short half-lives such as MCL-1, MYC, and cyclin
D1. A variety of CDK9 inhibitors investigated in preclin-
ical and clinical studies have demonstrated antiapoptotic
and antitumor effects. However, the lack of selectivity
for CDK9 may contribute to the less than optimal clin-
ical efficacy and side effect profiles seen with CDK9 in-
hibitors thus far, necessitating investigation into more
targeted approaches to improve outcome. Also the opti-
mal pharmacokinetic profile and dosing schedule for
CDK9 inhibitors is yet to be determined. In addition to
use of predictive biomarkers, another rational approach is
targeting multiple survival pathways, such as targeting
both CDK9 and BRD4 to overcome increased MYC ex-
pression induced by CDK9 inhibition, or dual inhibition
of both CDK9 and BCL family members [90, 91].
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